|7 November 2017|
Nestlé Health Science is making a multi-million dollar investment in a biopharmaceutical company developing pioneering therapies to combat life-threatening food allergies.
The $145 million collaboration with Aimmune Therapeutics will support ‘the development and commercialisation of innovative food allergy therapies’.
Aimmune Therapeutics is developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) to improve the lives of millions worldwide.
Aimmune CEO Stephen Dilly said: “Nestlé Health Science is an ideal partner that brings a shared vision, global scale and complementary capabilities to this collaboration, making the whole more than the sum of the parts. We are excited to have Nestlé Health Science alongside as we pursue our development plans and seek to realize the full promise of our CODIT approach by addressing the important questions in food allergy around optimising treatments, achieving sustained unresponsiveness, and exploring the science around tolerance.”
Greg Behar, CEO of Nestlé Health Science, added: “Food allergies have a huge personal impact and are a health economic burden. Nestlé Health Science is investing and innovating to change the approach to food allergy management, with integrated approaches from diagnostics to nutrition solutions and now biologics, where Aimmune’s proprietary approach has transformational potential in the lives of patients and families.”